UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 2, 2015
PROVECTUS BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)
|
|
|
|
|
Delaware |
|
001-36457 |
|
90-0031917 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
7327 Oak Ridge Hwy., Knoxville, Tennessee 37931
(Address of Principal Executive Offices)
(866) 594-5999
(Registrants Telephone Number, Including Area Code)
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. |
Regulation FD Disclosure. |
On July 2, 2015, Provectus Biopharmaceuticals, Inc. (the
Company) issued a press release (the ESMO Press Release) announcing that data from its phase 1 study of PV-10, the Companys novel investigational drug for cancer (PV-10), for chemoablation of hepatocellular
carcinoma and cancer metastatic to the liver was presented at the ESMO 17th World Congress on Gastrointestinal Cancer. A copy of the ESMO Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
On July 2, 2015, the Company issued a press release (the Boehringer Press Release) announcing that it has signed a Letter of
Intent (the LOI) with Boehringer Ingelheim (China) Investment Co. Ltd. (Boehringer). The purpose of the LOI is to lay a foundation for the Company and Boehringer to collaborate in bringing PV-10 to market in mainland China,
Hong Kong and Taiwan. Maxim Group LLC acted as strategic advisor to the Company in structuring and negotiating the LOI. A copy of the Boehringer Press Release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
Pursuant to the rules and regulations of the Securities and Exchange Commission, the information in this Item 7.01 disclosure, including
Exhibits 99.1 and 99.2 and information set forth therein, is deemed to have been furnished and shall not be deemed to be filed under the Securities Exchange Act of 1934.
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits.
|
|
|
Exhibit Number |
|
Description |
|
|
99.1 |
|
ESMO Press Release, dated July 2, 2015 |
|
|
99.2 |
|
Boehringer Press Release, dated July 2, 2015 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: July 2, 2015
|
|
|
PROVECTUS BIOPHARMACEUTICALS, INC. |
|
|
By: |
|
/s/ Peter R. Culpepper |
|
|
Peter R. Culpepper |
|
|
Chief Financial Officer and Chief Operating Officer |
2
EXHIBIT INDEX
|
|
|
Exhibit Number |
|
Description |
|
|
99.1 |
|
ESMO Press Release, dated July 2, 2015 |
|
|
99.2 |
|
Boehringer Press Release, dated July 2, 2015 |
Exhibit 99.1
|
|
|
Contact: |
|
|
Provectus Biopharmaceuticals, Inc. |
|
Porter, LeVay & Rose, Inc. |
Peter R. Culpepper, CFO, COO |
|
Marlon Nurse, DM, SVP Investor Relations |
Phone: 866-594-5999 #30 |
|
Phone: 212-564-4700 |
|
|
Todd Aydelotte Media Relations |
|
|
Phone: 646-428-0644 |
FOR IMMEDIATE RELEASE
Provectus Biopharmaceuticals Data on PV-10 for Chemoablation of Liver Cancers Presented at ESMO 17th World Congress on Gastrointestinal Cancer
Preliminary Evidence of Efficacy
Observed
KNOXVILLE, Tenn. July 2, 2015 Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT,www.pvct.com), a clinical-stage oncology and
dermatology biopharmaceutical company (Provectus or the Company), announced that data from its phase 1 study of PV-10 for chemoablation of hepatocellular carcinoma (HCC) and cancer metastatic to the liver was presented at the
ESMO 17th World Congress on Gastrointestinal Cancer (ESMO-GI). The main conclusion was that preliminary evidence of efficacy in treatment of liver cancers with PV-10 was observed. The poster
presentation was made by Eric Wachter, Ph.D., Chief Technology Officer of Provectus.
Provectus has previously reported data on clinical and nonclinical
testing of intralesional PV-10, a 10% solution of rose bengal, as an investigational treatment for metastatic melanoma, where it has demonstrated high rates of complete response and durable local control in melanoma lesions. The current phase 1
study reported at ESMO-GI was designed to assess safety, pharmacokinetics, and preliminary efficacy of PV-10 in subjects with non-resectable HCC or other types of cancer metastatic to the liver.
In the phase 1 liver study, subjects having a target lesion in the liver at least 1 cm in diameter were administered a single percutaneous injection of PV-10
into their target lesion. Plasma concentrations of PV-10 from 1 hour to 28 days after injection were measured. Radiologic assessments of the injected target lesion were performed to determine response over an initial 28-day and longer term 9-15
month follow-up period. Serum levels of potential liver injury markers were measured, and adverse events recorded.
In the initial study cohort, six
subjects received PV-10 injections in two successive escalating dose cohorts of 0.25 and 0.50 mL per cm3 lesion volume. Significant adverse events were limited to injection site and photosensitivity reactions that resolved without sequelae. All
injected tumors were stable in size at 28 days, and among four of the initial six tumors that had longer-term assessment, two had partial response.
Based on these data, the researchers concluded that preliminary efficacy in treatment of liver tumors with PV-10
was observed with acceptable tolerability. The study is continuing at three study centers with two expansion cohorts to further assess safety and response in HCC and other cancers metastatic to the liver.
The poster is now available online at: http://www.pvct.com/publications/ESMO-2015-PV-10-LC-01.pdf.
About ESMO 17th World Congress on Gastrointestinal Cancer
The ESMO 17th World Congress on Gastrointestinal Cancer is the premier global event in the field,
encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon
tumors. For additional information about the ESMO 17th World Congress, please visit http://worldgicancer.com/WCGI/WGIC2015/index.asp.
About Provectus Biopharmaceuticals, Inc.
Provectus
Biopharmaceuticals, Inc. specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for
systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical
investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis
and psoriasis. Information about these and the Companys other clinical trials, including its current phase 3 study in melanoma, can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit
the Companys website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains
forward-looking statements as defined under U.S. federal securities laws. These statements reflect managements current knowledge, assumptions, beliefs, estimates, and expectations and express managements current views of
future performance, results, and trends and may be identified by their use of terms such as anticipate, believe, could, estimate, expect, intend, may,
plan, predict, project, will, and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those
described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to materially differ from those described in
forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2014) and the following:
|
|
|
our determination, based on guidance from the FDA, whether to proceed with or without a partner with the fully enrolled phase 3 trial of PV-10 to treat locally advanced cutaneous melanoma and the costs associated with
such a trial if it is necessary to complete (versus interim data alone); |
|
|
|
our determination whether to license PV-10, our melanoma drug product candidate, and other solid tumors such as cancers of the liver, if such licensure is appropriate considering the timing and structure of such a
license, or to commercialize PV-10 on our own to treat melanoma and other solid tumors such as cancers of the liver; |
|
|
|
our ability to license our dermatology drug product candidate, PH-10, on the basis of our phase 2 atopic dermatitis and psoriasis results, which are in the process of being further developed in conjunction with
mechanism of action studies; and |
|
|
|
our ability to raise additional capital if we determine to commercialize PV-10 and/or PH-10 on our own, although our expectation is to be acquired by a prospective pharmaceutical or biotech concern prior to
commercialization. |
###
Exhibit 99.2
|
|
|
Contact: |
|
|
Provectus Biopharmaceuticals, Inc. |
|
Porter, LeVay & Rose, Inc. |
Peter R. Culpepper, CFO, COO |
|
Marlon Nurse, DM, SVP Investor Relations |
Phone: 866-594-5999 #30 |
|
Phone: 212-564-4700 |
|
|
Todd Aydelotte Media Relations |
|
|
Phone: 646-428-0644 |
FOR IMMEDIATE RELEASE
PROVECTUS BIOPHARMACEUTICALS SIGNS LETTER OF INTENT WITH BOEHRINGER INGELHEIM (CHINA) TO COLLABORATE IN BRINGING PV-10 TO MARKET IN CHINA
LOI Signed at ESMO GI Addresses Melanoma and Cancers of the Liver
KNOXVILLE, TN, July 2, 2015 Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology
biopharmaceutical company (Provectus or the Company), announced today that it has signed a Letter of Intent (the LOI) with Boehringer Ingelheim (China) Investment Co. Ltd. (Boehringer). The purpose of
the LOI is to lay a foundation for the two parties to collaborate in bringing PV-10, Provectus novel investigational drug for cancer (PV-10), to market in mainland China, Hong Kong and Taiwan. Maxim Group LLC acted as strategic
advisor to Provectus in structuring and negotiating the LOI.
Under the terms of the LOI, Boehringer will provide certain commercially reasonable support
in the aspects of product registration with the China Food and Drug Administration (CFDA), communication preparation, market intelligence and other assistance to Provectus in China to the extent that is within Boehringers approved
business scope and permissible by Chinese laws.
In return, Provectus will grant Boehringer the first priority to be the exclusive collaborator of
Provectus in China for PV-10 in the event that PV-10 is successfully registered and approved by the CFDA. The exclusive collaboration may take the form of exclusive distribution and promotion, exclusive licensing or other agreement, subject to both
parties mutual agreement. At the appropriate time, Provectus and Boehringer will enter into a definitive agreement, including a non-compete provision, for PV-10 to be exclusively developed, distributed and promoted through the collaboration
within China, although there can be no assurance that the parties will enter into a definitive agreement.
In the LOI signed today at the European Society
for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2015 in Barcelona, the two parties have agreed to meet regularly and maintain effective communication in order to move forward with the registration and commercialization of the
product and assess the potential cooperation between them in China, which may be adopted in a form of exclusive commercial supply, distribution and promotion, partnership or any other forms suitable to both parties interests.
Stephen Doyle, Vice President and Head of Specialty Care, China, at Boehringer, said, We are impressed with the work the management of Provectus and its
researchers have done so far in developing PV-10 as a potential treatment option for melanoma and cancers of the liver. At
Boehringer Ingelheim we are committed to research and development in areas of high unmet need such as liver cancer. If successful, we believe that many Chinese patients could benefit from being
treated with PV-10. Because of this, and the data generated so far, we are prepared to provide the commercially reasonable support Provectus may need to get PV-10 through the drug development and registration approval process in China.
Peter Culpepper, CFO and COO of Provectus, said, We are excited about the potential of PV-10 in China and in commencing a working relationship with
Boehringer Ingelheim to bring PV-10 to market there. We are confident that Boehringer Ingelheims expertise in navigating the regulatory requirements in China will prove beneficial to us, and we are also confident that a commercial
collaboration will benefit both companies. In addition, we believe that a successful partnership with Boehringer Ingelheim in China will provide us with experience in dealing with regulatory systems outside the US and help us take PV-10 to a global
marketplace.
About Boehringer Ingelheim
The
Boehringer Ingelheim group is one of the worlds 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of
the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such
as the initiative Making more Health and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental
protection and sustainability.
In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to
19.9 per cent of its net sales.
For more information please visit www.boehringer-ingelheim.com
About Provectus Biopharmaceuticals, Inc.
Provectus
Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for
systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical
investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis
and psoriasis. Information about these and the Companys other clinical trials, including its current phase 3 study in melanoma, can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit
the Companys website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains
forward-looking statements as defined under U.S. federal securities laws. These statements reflect managements current knowledge, assumptions, beliefs, estimates, and expectations and express managements current views of
future performance, results, and trends and may be identified by their use of terms such as anticipate, believe, could, estimate, expect, intend, may,
plan, predict, project, will, and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those
described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to materially differ from those described in
forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2014) and the following:
|
|
|
our determination, based on guidance from the FDA, whether to proceed with or without a partner with the fully enrolled phase 3 trial of PV-10 to treat locally advanced cutaneous melanoma and the costs associated with
such a trial if it is necessary to complete (versus interim data alone); |
|
|
|
our determination whether to license PV-10, our melanoma drug product candidate, and other solid tumors such as cancers of the liver, if such licensure is appropriate considering the timing and structure of such a
license, or to commercialize PV-10 on our own to treat melanoma and other solid tumors such as cancers of the liver; |
|
|
|
our ability to license our dermatology drug product candidate, PH-10, on the basis of our phase 2 atopic dermatitis and psoriasis results, which are in the process of being further developed in conjunction with
mechanism of action studies; and |
|
|
|
our ability to raise additional capital if we determine to commercialize PV-10 and/or PH-10 on our own, although our expectation is to be acquired by a prospective pharmaceutical or biotech concern prior to
commercialization. |
###
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From May 2023 to May 2024